Gunderson Dettmer advised Histogenics Corporation on a follow-on public offering underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
